GS030 is an innovative optogenetic treatment that started a Phase I/II PIONEER clinical trial in Europe and US with patients affected by Retinitis Pigmentosa (RP).
GS030 – Optogenetics in Retinitis Pigmentosa (RP)
Free-Paper Title: Optogenetics in the clinic: PIONEER: a phase 1/2 open-label, non-randomized, dose-escalation study to evaluate safety and tolerability of GS030 in subjects with retinitis pigmentosa
- Presenting Author: Katz, Chief Medical Officer, GenSight Biologics, United States
- Session Title: Quick-Fire Free Papers Session
- Date/Time: Saturday 02 March 2019, 12:00 pm
- Room: Clarion Congress Hotel Prague
- Theme: Miscellaneous